New lung drug ENV-101 put through safety checks in healthy volunteers
Knowledge-focused
Recruiting now
This early-stage study tests how a new drug called ENV-101 (taladegib) interacts with two standard medicines for idiopathic pulmonary fibrosis (IPF): nintedanib and pirfenidone. About 57 healthy adults will take ENV-101 alone and with these drugs to measure how the body absorbs a…
Phase: PHASE1 • Sponsor: Endeavor Biomedicines, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC